Instem is now beginning to see the benefits of years of investment to support the FDA’s SEND initiative with strong demand in evidence for its tech-enabled outsourced services. The focus on driving SaaS and other recurring revenues is also improving margins and quality of earnings. FY18 results were in line with expectations after adjusting for IFRS15. Headline forecasts are unchanged and we continue to believe the shares offer a compelling opportunity. Instem remains a Best Idea for 2019.
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Reaping the rewards of investment
- Published:
01 Apr 2019 -
Author:
Chris Glasper -
Pages:
3
Instem is now beginning to see the benefits of years of investment to support the FDA’s SEND initiative with strong demand in evidence for its tech-enabled outsourced services. The focus on driving SaaS and other recurring revenues is also improving margins and quality of earnings. FY18 results were in line with expectations after adjusting for IFRS15. Headline forecasts are unchanged and we continue to believe the shares offer a compelling opportunity. Instem remains a Best Idea for 2019.